Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc.
Your view on ARCT
Overview
What the company does, where it operates, and who runs it.
About Arcturus Therapeutics Holdings Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joseph E. Payne
- Headquarters
- 10628 Science Center Drive, San Diego, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Joseph E. Payne
- Headquarters
- 10628 Science Center Drive, San Diego, CA, US
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States.
The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.
It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis.
The company was founded in 2013 and is headquartered in San Diego, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Arcturus Therapeutics Holdings Inc., and the rating behind it. ARCT last traded at $14.73; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Arcturus Therapeutics Holdings Inc.. Starting points for Arcturus Therapeutics Holdings Inc.: EPS -$3.28, beta 2.48 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Arcturus Therapeutics Holdings Inc.. Arcturus Therapeutics Holdings Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Arcturus Therapeutics Holdings Inc.. Trailing twelve-month EPS for Arcturus Therapeutics Holdings Inc. stands at -$3.28. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Arcturus Therapeutics Holdings Inc.. Arcturus Therapeutics Holdings Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Arcturus Therapeutics Holdings Inc. valued side by side against its closest peers. Arcturus Therapeutics Holdings Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Arcturus Therapeutics Holdings Inc., and how their positions are changing. At a $418.7M market value, institutional positions materially move Arcturus Therapeutics Holdings Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Arcturus Therapeutics Holdings Inc. executives and directors. Shares of Arcturus Therapeutics Holdings Inc. have traded between $6.57 and $24.17 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Arcturus Therapeutics Holdings Inc.. Arcturus Therapeutics Holdings Inc. is a $418.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Arcturus Therapeutics Holdings Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Arcturus Therapeutics Holdings Inc.. Coverage tracks Arcturus Therapeutics Holdings Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.